These patients tend to show a poor clinical outcome and poor disease-specific survival.23, 24 Furthermore, periostin was detectable in the serum of early breast cancer patients before surgery and increased baseline serum levels predicted worse long-term survival outcomes in specific subgroups of patients.25 Similarly, upregulation of periostin is seen in non-small-cell lung and prostate cancer and correlates with disease stage.26, 27 Our report is the first, according to our knowledge, which shows high levels of periostin in myeloma patients that correlate with adverse disease features. The gene discussed is POSTN; the disease is breast carcinoma.